poisar

Stocks · News reference

AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study

Benzinga Newsdesk

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AIM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

    AIM ImmunoTech announced patent protection for Ampligen across 18 European countries and the United Kingdom through June 2041 for Long COVID treatment. The company also recently secured a U.S. patent for Ampligen combined with pembrolizumab for cancer treatment. These patents strengthen AIM's global intellectual property position around its dsRNA immunomodulator platform across multiple therapeutic indications.

    AIM